Literature DB >> 6190539

Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains.

A Mauborgne, F Javoy-Agid, J C Legrand, Y Agid, F Cesselin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6190539     DOI： 10.1016/0006-8993(83)90403-1

Source DB:  PubMed          Journal:  Brain Res        ISSN： 0006-8993            Impact factor:   3.252


× No keyword cloud information.
  10 in total

1.  Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain.

Authors:  W S Young; T I Bonner; M R Brann
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

2.  Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation.

Authors:  N Lindefors; E Brodin; U Tossman; J Segovia; U Ungerstedt
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

Review 3.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

4.  Neuropeptide gene expression in brain is differentially regulated by midbrain dopamine neurons.

Authors:  N Lindefors; S Brené; M Herrera-Marschitz; H Persson
Journal:  Exp Brain Res       Date:  1990       Impact factor: 1.972

Review 5.  The mammalian tachykinin ligand-receptor system: an emerging target for central neurological disorders.

Authors:  Nick Pantaleo; Wayne Chadwick; Sung-Soo Park; Liyun Wang; Yu Zhou; Bronwen Martin; Stuart Maudsley
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-11       Impact factor: 4.388

Review 6.  Demystifying the Neuroprotective Role of Neuropeptides in Parkinson's Disease: A Newfangled and Eloquent Therapeutic Perspective.

Authors:  Tapan Behl; Piyush Madaan; Aayush Sehgal; Sukhbir Singh; Hafiz A Makeen; Mohammed Albratty; Hassan A Alhazmi; Abdulkarim M Meraya; Simona Bungau
Journal:  Int J Mol Sci       Date:  2022-04-20       Impact factor: 6.208

7.  Methionine-enkephalin and substance P in the basal ganglia of normals, Parkinson patients, Huntington patients, and schizophrenics. A qualitative immunohistochemical study.

Authors:  M Zech; B Bogerts
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

8.  Increased calcitonin gene-related peptide- and cholecystokinin-like immunoreactivities in spinal motoneurones after dorsal rhizotomy.

Authors:  H Taquet; J J Plachot; M Pohl; E Collin; J J Benoliel; S Bourgoin; A Mauborgne; J C Meunier; F Cesselin; M Hamon
Journal:  J Neural Transm Gen Sect       Date:  1992

9.  Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease.

Authors:  Emma Thornton; Robert Vink
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

10.  Mapping of neurokinin-like immunoreactivity in the human brainstem.

Authors:  Rafael Coveñas; Francisco Martin; Magdalena Belda; Victor Smith; Pablo Salinas; Eva Rivada; Zaida Diaz-Cabiale; Jose Angel Narvaez; Pilar Marcos; Gerard Tramu; Salvador Gonzalez-Baron
Journal:  BMC Neurosci       Date:  2003-02-04       Impact factor: 3.288
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.